Risk Factors for Venous Thromboembolism in Children Undergoing Orthopedic Surgery

Object The risk of venous thromboembolism (VTE) in children with traumatic brain injury (TBI) has not been well characterized given its rarity in the pediatric population. Investigation of risk factors for VTE in this group requires the use of a large sample size. Using nationally representative hospital discharge data for 2009, the authors of this study characterize the incidence and risk factors for VTE in children hospitalized for TBI. Methods The authors conducted a cross-sectional study using data from the Healthcare Cost and Utilization Project Kids' Inpatient Database to examine VTE in TBI-associated hospitalizations for patients 20 years of age or younger during the year 2009. Results There were 58,529 children with TBI-related admissions, including 267 with VTE diagnoses. Venous thromboembolisms occurred in 4.6 per 1000 TBI-associated hospitalizations compared with 1.2 per 1000 pediatric hospitalizations overall. By adjusted logistic regression, patients significantly more likely to be diagnosed with VTE had the following: older age of 15–20 years (adjusted odds ratio [aOR] 3.7, 95% CI 1.8–8.0), venous catheterization (aOR 3.0, 95% CI 2.0–4.6), mechanical ventilation (aOR 1.9, 95% CI 1.2–2.9), tracheostomy (aOR 2.3, 95% CI 1.3–4.0), nonaccidental trauma (aOR 2.8, 95% CI 1.1–6.9), increased length of stay (aOR 1.02, 95% CI 1.01–1.03), orthopedic surgery (aOR 2.4, 95% CI 1.8–3.4), and cranial surgery (aOR 1.8, 95% CI 1.1–2.8). Conclusions Using the Kids' Inpatient Database, the authors found that risk factors for VTE in the setting of TBI in the pediatric population include older age, venous catheterization, nonaccidental trauma, increased length of hospital stay, orthopedic surgery, and cranial surgery.

Download Full-text

TL 18040 - Venous thromboembolism risk in foot and ankle surgical patients

Scientific Journal of the Foot & Ankle ◽

10.30795/scijfootankle.2019.v13.1004 ◽

2019 ◽

Vol 13 (Supl 1) ◽

pp. 62S

Author(s):

Roberto Zambelli de Almeida Pinto ◽

Banne Nemeth ◽

Carolina Touw ◽

Suely Rezende ◽

Suzanne Cannegieter

Keyword(s):

Risk Factors ◽

Venous Thromboembolism ◽

Venous Thrombosis ◽

Orthopedic Surgery ◽

Index Date ◽

Elective Surgery ◽

Foot And Ankle ◽

Increased Risk ◽

Ankle Surgery ◽

First 90 Days

Introduction: Venous thromboembolism (VTE) is the leading cause of preventable hospital death. There are several risk factors for VTE, of which orthopedic surgery is an important one. VTE risk is highest following major orthopedic surgery, and therefore, some form of prophylactic therapy is usually recommended. In contrast, the risk for VTE following foot and ankle surgery is less clear, as are guidelines on VTE prophylaxis in these patients. Objective: To estimate the risk of VTE and the duration of the increased risk period after foot and ankle surgery. Methods: Data from a large population-based case–control study (the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis [MEGA] study) on the etiology of venous thrombosis were used (4721 cases; 5638 controls). Odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for age, sex and body mass index (ORadj), were calculated for patients undergoing any foot or ankle intervention before the index date (VTE date or control date). Results: The 263 cases and 94 controls underwent any orthopedic intervention in the year before the index date for an ORadj of 3,74 (95% CI 2,91-4,80) The ORadj in the first 90 days was 11,35 (95% CI 7,28-17,70). Fifty-five cases and 20 controls had a foot or ankle intervention in the year before the index date, resulting in a three-fold increased risk for VTE (OR 3,29, 95% CI 1,98-5,49). VTE risk was highest in the first 30 (ORadj 10,15 (95% CI 3,04-33,85)) and 90 days following surgery (ORadj 12,42, 95% CI 4,43-34,84). In 34 patients, the surgery was trauma-related, while 43 patients underwent elective surgery. Traumatic surgery was associated with a higher risk than elective surgery with an OR of 13,85 (95% CI 1,77-108,36) and 8,32 (95% CI 1,87-36,94), respectively, at 30 days. Conclusion: Foot and ankle procedures were associated with an increased VTE risk, which was highest in the first 90 days following surgery. Trauma-related surgery was associated with a higher VTE risk than elective surgery. These results are important for decisions regarding thromboprophylactic measures following foot and ankle surgery.

Download Full-text

Venous Thromboembolism Prevention with LMWHs in Medical and Orthopedic Surgery Patients

Annals of Pharmacotherapy ◽

10.1345/aph.1c152 ◽

2003 ◽

Vol 37 (3) ◽

pp. 402-411 ◽

Cited By ~ 8

Author(s):

Steven B Deitelzweig ◽

Gordon J Vanscoy ◽

Cynthia S Niccolai ◽

Thomas L Rihn

Keyword(s):

Risk Factors ◽

Molecular Weight ◽

Venous Thromboembolism ◽

Orthopedic Surgery ◽

Low Molecular Weight ◽

Medical Patients ◽

Efficacy And Safety ◽

Consensus Guidelines ◽

Medline Search ◽

Vte Prophylaxis

OBJECTIVE: To discuss the role of low-molecular-weight heparins (LMWHs) in the prevention of venous thromboembolism (VTE) in medical and orthopedic surgery patients. VTE prophylaxis trials in these practice settings establishing the current use of LMWHs marketed in the US are included. An overview is also provided of VTE incidence, risk factors, and prophylaxis consensus guidelines. DATA SOURCES AND STUDY SELECTION: Clinical trials, review articles, and meta-analyses for Food and Drug Administration–approved LMWHs were identified from a MEDLINE search (1980–March 2002). Search terms included dalteparin, enoxaparin, internal medicine, low-molecular-weight heparin, orthopedic surgery, risk factors, tinzaparin, and venous thromboembolism. DATA SYNTHESIS: Consensus guidelines are useful as an initial guide to appropriate VTE prophylaxis; however, a review of the primary literature is needed to identify optimal agents, regimens, or interventions. LMWHs have demonstrated sound efficacy in VTE prevention; however, the quantity and quality of literature are not always comparable for the available agents. CONCLUSIONS: Enoxaparin has demonstrated efficacy and safety in VTE prevention in medical patients, whereas information is limited or lacking for dalteparin and tinzaparin. Total hip replacement (THR) trials have been conducted with all US-marketed LMWHs and have demonstrated the efficacy and safety of each agent. Trials specifically establishing the efficacy of an LMWH in total knee replacement surgery (TKR) have been published for enoxaparin. One combination THR and TKR trial has been published for tinzaparin. These trial outcomes have positioned the LMWHs as key alternatives to adjusted-dose warfarin for VTE prophylaxis in orthopedic surgery. Inherent differences between LMWHs prevent the extrapolation of clinical outcomes from 1 trial to another.

Download Full-text

Can We Do Better? Identifying Orthopedic Surgery Patients at High Risk for Venous Thromboembolism Despite Thromboprophylaxis.

Blood ◽

10.1182/blood.v104.11.1782.1782 ◽

2004 ◽

Vol 104 (11) ◽

pp. 1782-1782

Author(s):

Susan R. Kahn ◽

Renee L. Schiff ◽

Ian Shrier ◽

Wahbi Hammouda ◽

David Zukor

Keyword(s):

Risk Factors ◽

Molecular Weight ◽

Venous Thromboembolism ◽

Confidence Interval ◽

Orthopedic Surgery ◽

Low Molecular Weight Heparin ◽

Patient Characteristics ◽

Low Molecular Weight ◽

Care Hospital ◽

Major Orthopedic Surgery

Abstract Background Routine administration of thromboprophylaxis is the standard of care for patients undergoing major orthopedic surgery due to the very high rate of postoperative venous thromboembolism (VTE). However, because prophylaxis is not 100% effective, a significant proportion of patients who receive thromboprophylaxis develop post-operative VTE (“breakthrough VTE”). Clinical and surgical characteristics that are associated with the development of VTE in orthopedic surgery patients who receive standard thromboprophylaxis have not been well characterized. Objectives To evaluate the incidence of and risk factors for breakthrough VTE in patients who underwent major orthopedic surgery at a tertiary care hospital in Montreal, Canada. Methods Charts from consecutive patients who underwent total hip arthroplasty (THA), total knee arthroplasty (TKA) or hip fracture surgery (HFS) (hip pinning or hemiarthroplasty) from August 1, 1999 to April 30, 2000 were abstracted using standardized case report forms. Data were collected on patient characteristics (including VTE risk factors and postoperative complications), surgical characteristics (including type of surgery, operative factors, type of anesthetic) and thromboprophylaxis regimen. The results of any tests performed for clinically suspected VTE were documented, and associations between potential risk factors and objectively confirmed VTE were examined. Results Over the 9 month study period, 310 patients underwent major orthopedic surgery (34% THA, 30% TKA, and 36% HFS) and received standard thromboprophylaxis with either dalteparin or enoxaparin (mean duration of prophylaxis: 7 days). Of 83 suspected VTE, 44 (7 proximal DVTs and 37 distal DVTs; 14% of study population; median onset 6 days post-op) were confirmed with objective testing (compression ultrasonography). Multivariate analyses showed that knee surgery (odds ratio [OR] 4.8, 95% confidence interval 2.3, 10.1) and type of low molecular weight heparin (enoxaparin: protective) (OR 0.39, 95% confidence interval 0.20, 0.80) independently predicted VTE. Patient characteristics such as previous VTE, malignancy, hormonal therapy or varicose veins were not associated with VTE. Conclusion Despite receiving standard thromboprophylaxis, 14% of patients undergoing major orthopedic surgery developed symptomatic breakthrough VTE. Factors that independently predicted VTE in our population were TKR surgery and type of low molecular weight heparin. Our results suggest that TKR patients may warrant more aggressive post-operative physiotherapy and ambulation and adjunctive prophylactic measures such as pneumatic compression. In addition, due to the heterogeneity of different low molecular weight heparin compounds, direct comparison of the effectiveness of enoxaparin with dalteparin for orthopedic prophylaxis in prospective, randomized trials seems warranted.

Download Full-text

Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points

Yearbook of Pulmonary Disease ◽

10.1016/s8756-3452(08)70118-x ◽

2006 ◽

Vol 2006 ◽

pp. 148-151

Author(s):

K.L. Lewis

Keyword(s):

Venous Thromboembolism ◽

Orthopedic Surgery ◽

End Points ◽

Major Orthopedic Surgery

Download Full-text

Premature Arterial Disease Associated with Familial Antithrombin III Deficiency

Thrombosis and Haemostasis ◽

10.1055/s-0038-1645677 ◽

1990 ◽

Vol 63 (01) ◽

pp. 013-015 ◽

Cited By ~ 15

Author(s):

E J Johnson ◽

C R M Prentice ◽

L A Parapia

Keyword(s):

Risk Factors ◽

Venous Thromboembolism ◽

Potential Risk ◽

Antithrombin Iii ◽

Arterial Disease ◽

Coagulation System ◽

Early Age ◽

Arterial Thromboembolism ◽

Potential Risk Factors ◽

Antithrombin Iii Deficiency

SummaryAntithrombin III (ATIII) deficiency is one of the few known abnormalities of the coagulation system known to predispose to venous thromboembolism but its relation to arterial disease is not established. We describe two related patients with this disorder, both of whom suffered arterial thrombotic events, at an early age. Both patients had other potential risk factors, though these would normally be considered unlikely to lead to such catastrophic events at such an age. Thrombosis due to ATIII deficiency is potentially preventable, and this diagnosis should be sought more frequently in patients with arterial thromboembolism, particularly if occurring at a young age. In addition, in patients with known ATIII deficiency, other risk factors for arterial disease should be eliminated, if possible. In particular, these patients should be counselled against smoking.

Download Full-text

Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism

Thrombosis and Haemostasis ◽

10.1055/s-0038-1650643 ◽

1996 ◽

Vol 76 (05) ◽

pp. 682-688 ◽

Cited By ~ 33

Author(s):

Jos P J Wester ◽

Harold W de Valk ◽

Karel H Nieuwenhuis ◽

Catherine B Brouwer ◽

Yolanda van der Graaf ◽

...

Keyword(s):

Risk Factors ◽

Venous Thromboembolism ◽

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Small Body ◽

Bleeding Risk ◽

Risk Scores ◽

Risk Of Bleeding ◽

Acute Venous Thromboembolism

Summary Objective: Identification of risk factors for bleeding and prospective evaluation of two bleeding risk scores in the treatment of acute venous thromboembolism. Design: Secondary analysis of a prospective, randomized, assessor-blind, multicenter clinical trial. Setting: One university and 2 regional teaching hospitals. Patients: 188 patients treated with heparin or danaparoid for acute venous thromboembolism. Measurements: The presenting clinical features, the doses of the drugs, and the anticoagulant responses were analyzed using univariate and multivariate logistic regression analysis in order to evaluate prognostic factors for bleeding. In addition, the recently developed Utrecht bleeding risk score and Landefeld bleeding risk index were evaluated prospectively. Results: Major bleeding occurred in 4 patients (2.1%) and minor bleeding in 101 patients (53.7%). For all (major and minor combined) bleeding, body surface area ≤2 m2 (odds ratio 2.3, 95% Cl 1.2-4.4; p = 0.01), and malignancy (odds ratio 2.4, 95% Cl 1.1-4.9; p = 0.02) were confirmed to be independent risk factors. An increased treatment-related risk of bleeding was observed in patients treated with high doses of heparin, independent of the concomitant activated partial thromboplastin time ratios. Both bleeding risk scores had low diagnostic value for bleeding in this sample of mainly minor bleeders. Conclusions: A small body surface area and malignancy were associated with a higher frequency of bleeding. The bleeding risk scores merely offer the clinician a general estimation of the risk of bleeding. In patients with a small body surface area or in patients with malignancy, it may be of interest to study whether limited dose reduction of the anticoagulant drug may cause less bleeding without affecting efficacy.

Download Full-text

Venous Thromboembolism and High Grade Gliomas

Thrombosis and Haemostasis ◽

10.1055/s-0038-1649592 ◽

1993 ◽

Vol 70 (03) ◽

pp. 393-396 ◽

Cited By ~ 38

Author(s):

Mandeep S Dhami ◽

Robert D Bona ◽

John A Calogero ◽

Richard M Hellman

Keyword(s):

Risk Factors ◽

Venous Thromboembolism ◽

Medical Center ◽

Significant Risk ◽

Bleeding Complications ◽

Fisher Exact Test ◽

High Grade ◽

Chi Square ◽

Exact Test ◽

High Grade Gliomas

SummaryA retrospective study was done to determine the incidence of and the risk factors predisposing to clinical venous thromboembolism (VTE) in patients treated for high grade gliomas. Medical records of 68 consecutive patients diagnosed and treated at Saint Francis Hospital and Medical Center from January 1986 to June 1991 were reviewed. The follow up was to time of death or at least 6 months (up to December 1991). All clinically suspected episodes of VTE were confirmed by objective tests. Sixteen episodes of VTE were detected in 13 patients for an overall episode rate of 23.5%. Administration of chemotherapy (p = 0.027, two tailed Fisher exact test) and presence of paresis (p = 0.031, two tailed Fisher exact test) were statistically significant risk factors for the development of VTE. Thrombotic events were more likely to occur in the paretic limb and this difference was statistically significant (p = 0.00049, chi square test, with Yates correction). No major bleeding complications were seen in the nine episodes treated with long term anticoagulation.We conclude that venous thromboembolic complications are frequently encountered in patients being treated for high grade gliomas and the presence of paresis and the administration of chemotherapy increases the risk of such complications.

Download Full-text